Revance Therapeutics sells to Crown Laboratories
Crown Laboratories and its affiliate Reba Merger Sub will now pay for the shares, which will cost the company $314.6 million.
Polynucleotides Injectable Market Revenues to Grow by ~$100 Million During 2024-2030, Led by PharmaResearch, Bioplus Co, and AMEELA
Analysis of Global and Regional Markets by Application and End Use, Featuring Strategic Insights of Leading Players ...
Business Wire8d
Crown Laboratories Completes Acquisition of Revance Therapeutics
The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company ...
Mena FN16d
Medical Aesthetics Machine Market Set To Reach USD 30.7 Billion, With A Healthy 8.6% CAGR Till Forecasts 2032
AI-aided precision treatments and multifunctional aesthetics devices lead innovations. The future of healthcare is shaped by emerging technologies such as AI, robotics, and biotechnology. AI is ...
Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc.